Pakina V.A.

Pakina V.A.

Auto-generated profile, based on publicly available information

Pakina V.A.

National Research Nuclear University MEPhI, Moscow, Russian Federation

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2024 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
VPViktoria A. Pakina
Viktoria A. Pakina
EIEvgeniya Z. Iksanova
Evgeniya Z. Iksanova
ESEvgenia Shikh
Evgenia Shikh
OTOksana М. Tumutolova
Oksana М. Tumutolova
KAKaren K. Arutiunian
Karen K. Arutiunian
EBEkaterina Blinova
Ekaterina Blinova
Introduction: EGFR-activating overexpression or somatic mutations are common in different human cancers. In this regard, the search for promising ways to control the carcinogenic transformation of tumor cells and the progression of malignant tumors expressing EGFR seems to be one of the most promising and developing areas of modern molecular pathology and pharmacology. Material and Methods: An antitumor activity of a novel compound, a pyridine carboxylic acid derivative LHT-17-19, was studied. The molecule was developed and synthesized at the Department of Chemistry, Drug Design and Technology of All-Russian Research Center for Biological Active Compounds Safety (Russia). The study was carried out in cell cultures of stomach cancer (Hs746T, AGS and MKN1) and patient-derived organoid (PDO) model of breast cancer (BC) expressing wild-type EGFR. Results: It was shown that LHT-17-19 induced concentration-dependent cytotoxicity of EGFR-expressing gastric cancer cells of all the aforementioned cultures. Pathomorphological, immunohistochemical and molecular validation of BC organoids derived from ductal breast carcinoma cells of a 68-year-old patient was done. PDOs were established as ER-negative, PR-negative, Her2/neu-negative, EGFR-positive with 35% of the Ki-67 expression index. In addition, the tumor cells translocation was resulted in a loss of ER expression and PDOs molecular pattern conversion towards a more aggressive triple negative type. PDOs incubation with 0.5-60.0 µM LHT-17-19 was accompanied not only by inhibition of their growth and proliferation, but also by significant cytoreduction. Conclusion: Thus, in two-dimensional and three-dimensional tumor cell cultures, the possibility of controlling the oncogenic expression of EGFR with the acridone compound 9-ammonium-3,3-dimethyl-3,4-dihydroacridine-1(2H)-OH L-2-hydroxybutanedivacate (LHT-17-19) was shown.

25 September 2023 in Acta medica Eurasica
Verified
Journal Article
Closed access
ABAlina Bagdasaryan
Alina Bagdasaryan
EBEkaterina Blinova
Ekaterina Blinova
EKEkaterina A. Kutorkina
Ekaterina A. Kutorkina
VPVictoria A. Pakina
Victoria A. Pakina
AEAnna A. Epishkina
Anna A. Epishkina
DBDmitry Blinov
Dmitry Blinov
The basis of modern strategies for the treatment of oncological diseases is the use of pharmaceutical products. A high frequency of refractoriness and formation of tumor cells' resistance to anti-EGFR drugs dictates the need to develop new active inhibitors of this intracellular kinase. The aim of this work was to study the antitumor effect of a new compound – a derivative of 9-Dihydroacridone on in vitro models of EGFR-expressing tumor cells. Material and methods. The compound of 9-aminium-3,3-dimethyl-3,4-dihydroacridine-1(2H)-one L-2-hydroxy-butandiovate (laboratory cipher of the developer institution LHT-17-19) was studied. Three cultures of human stomach cancer were used for the study. The analysis of tumor cell growth suppression was performed in a test with 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide, intracellular identification of the phosphorylated form of receptor tyrosine kinase – by Western blotting. Study results. The compound of 9-dihydroacridone dose-dependently suppresses the growth of EGFR-expressing tumor cells of human gastric cancer. Hs746T culture cells have the greatest sensitivity to the compound, MKN1 has the least. The antitumor activity of the substance is based on the ability to reduce the intracellular pool of the activated form of receptor tyrosine kinase EGFR. Conclusions. The obtained results allow enable to consider the compound LHT-17-19 as a promising compound for the subsequent preclinical study of its antitumor properties in animal systems.

30 September 2023 in Bulletin "Biomedicine and sociology"
Verified
Journal Article
Closed access
ABAlina Bagdasaryan
Alina Bagdasaryan
KEKutorkina E.A.
Kutorkina E.A.
PVPakina V.A.
Pakina V.A.
BEBogoslovskaya E.V.
Bogoslovskaya E.V.
DBDmitry Blinov
Dmitry Blinov
EBEkaterina Blinova
Ekaterina Blinova

30 April 2023 in Bulletin "Biomedicine and sociology"
Verified
Journal Article
Closed access
KEKutorkina E.A.
Kutorkina E.A.
LELitvin E.A.
Litvin E.A.
PVPakina V.A.
Pakina V.A.
PLPapusha L.I.
Papusha L.I.
IEIksanova E.Z.
Iksanova E.Z.
DBDmitry Blinov
Dmitry Blinov

28 June 2025 in Bulletin "Biomedicine and sociology"
Verified
Journal Article
Closed access
KIKargina I.V.
Kargina I.V.
PVPakina V.A.
Pakina V.A.
SDShimanovsky D.N.
Shimanovsky D.N.
KEKutorkina E.A.
Kutorkina E.A.
EBEkaterina Blinova
Ekaterina Blinova
STSamyshina T.A.
Samyshina T.A.
The study examined selenium nanoparticles (SeNPs) synthesized by laser ablation. In vitro experiments on human colorectal carcinoma HT29 cell culture were used to study the activity of selenium nanoparticles in suppressing tumor cell growth using a laboratory MTT test with calculation of the IC50 value in comparison with liposomal doxorubicin. Acute toxicity of selenium nanoparticles was determined on white outbred laboratory mice with intraperitoneal and intravenous administration with an assessment of lethal doses LD100 and LD50. Antitumor activity of selenium nanoparticles was studied on C57Bl/6 mice, which were transplanted with MC38 colorectal adenocarcinoma subcutaneously into the left hind paw of the mouse at a concentration of 106 cells per mouse. Starting from day 5, mice in the 3 intervention groups were intraperitoneally injected with SeNPs at doses of 10 mg/kg and 1 mg/kg, solubilized in sterile saline. Animals in the control group received the same volume of saline. Injections of SNPs were performed once a day for 14 days. For 20 days after the start of the experimental exposure, the animals were weighed daily and the size of their tumors was measured using an electronic caliper. It was shown that the liquid nanoform of selenium suppresses tumor cell growth in a wide range of concentrations, the average inhibitory concentration IC50 was 5.2 × 10-6 M, which allows us to confirm the presence of antitumor activity of SNPs in colorectal cancer cell culture. When determining the acute toxicity of selenium nanoparticles, the calculated values of LD50 for intraperitoneal administration were 502 [430 ÷ 575] mg/kg; LD100 in mice for intravenous administration was 415 [355 ÷ 480] mg/kg, which corresponds to class 3 – moderately toxic substances according to international regulations. In mice of the experimental group, no significant differences from the control were observed until the 9th day of injections of both doses of selenium nanoparticles, but starting from the 10th day of injections, a decrease in tumor volumes was observed compared to the control, and already on the 12th day, noticeable inhibition of tumor growth was observed. Moreover, this indicator was 2-2.5 times less than in the control, and there were no significant differences between the two experimental groups receiving different doses of selenium nanoparticles. The obtained results allow us to suggest that selenium nanoparticles have their own antitumor effect.

30 September 2025 in “Educational bulletin “Consciousness”
Verified
Journal Article
Closed access
IEIksanova E.Z.
Iksanova E.Z.
DODeryabina O.N.
Deryabina O.N.
TOTumutolova O.M.
Tumutolova O.M.
BEBogoslovskaya E.V.
Bogoslovskaya E.V.
PVPakina V.A.
Pakina V.A.
SESamishina E.A.
Samishina E.A.
The study involved a newovel compound, a benzoxazinone derivative Rog014. QSAR analysis was performed using the PASSonline software. The ADME methodology was used to predict pharmacokinetic parameters. Screening for antitumor activity of the compound included in the A549 tumor culture (human non-small cell lung adenocarcinoma); non-tumor human fetal lung fibroblasts MRC-5 were used for the primary safety assessment of the compound. As a result of bioinformatics prediction of biological activity of benzoxazine-2-thione compound Rog014, biological targets and types of action were established, which determine the possibility of implementing substances with antitumor activity. According to its physicochemical properties, the limiting substance has moderate lipophilicity, can be absorbed from the gastrointestinal tract, is able to penetrate the blood-brain barrier and, for determining the characteristics, can be considered as a candidate for drugs. When incubating A549 cell culture with benzoxazine-2-thione compound Rog014, IC50 was measured at 4.1 × 10-5 M; while incubation of human fibroblast culture during the study does not lead to an additional cellular side. Compound Rog014 can be considered as a candidate for an antitumor drug.